SCHEMBL6965414

SCHEMBL6965414

COc1cc(-c2cc(O)c(Sc3ccccc3C(C)C)c(=O)o2)ccc1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.47
CYP1A2 P05177 2/20 0.47
ALDH1A1 P00352 3/20 0.44
TSHR P16473 3/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 2/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 3/20 0.42
ABCB1 P08183 2/20 0.41
PTGES O14684 2/20 0.40
ALOX5 P09917 1/20 0.40
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
CYP1B1 Q16678 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6962847 0.89 BCHE (0.39) CYP1A1CYP1A2SMN1; SMN2MAPTABCB1
SCHEMBL6965151 0.86 ABCB1 (0.45) CYP1A1CYP1A2MAPTABCB1CYP1B1
SCHEMBL8537357 0.84 ABCB1 (0.44) HPGDMAPTABCB1RAB9ANPC1
SCHEMBL6957747 0.82 CYP1A1 (0.50) CYP1A1CYP1A2ALDH1A1TSHRKDM4E
SCHEMBL6954819 0.80 SYK (0.38) PTGESACHEKMT2A
SCHEMBL6961094 0.80 NTRK1 (0.49) CYP1A1CYP1A2ALDH1A1TSHRKDM4E
SCHEMBL6963494 0.79 PTGES (0.43) CYP1A1CYP1A2ALDH1A1TSHRKDM4E
SCHEMBL6966299 0.79 PPARD (0.41) KDM4ECSNK2A2CSNK2BCSNK2A1
SCHEMBL6960106 0.79 CYP19A1 (0.39) HPGDMAPTABCB1ACHE
SCHEMBL6961039 0.79 SMN1; SMN2 (0.46) CYP1A1CYP1A2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed